Life360 price target raised to $55 from $40 at JMP Securities
JMP Securities analyst Andrew Boone raised the firm’s price target on Life360 (LIF) to $55 from $40 and keeps an Outperform rating on the ...
JMP Securities Sticks to Its Buy Rating for PubMatic (PUBM)
In a report released today, Andrew Boone from JMP Securities maintained a Buy rating on PubMatic (PUBM – Research Report), with a price ...
bovnews3h
What’s Fueling Planet Labs PBC (PL) Stock’s 39.43% Gain Above Its 200-Day SMA?
On Wednesday, Planet Labs PBC (PL) stock saw a modest uptick, ending the day at $3 which represents a slight increase of $0.37 or 14.07% from the prior close of $2.63. The stock opened at $2.7 and ...
bovnews4h
Dave Inc (DAVE) Stock: A Deeper Look at Its True Potential
On Wednesday, Dave Inc (DAVE) stock saw a modest uptick, ending the day at $90.43 which represents a slight increase of $27.63 or 44.00% from the prior close of $62.8. The stock opened at $78.25 and ...
Fintel on MSN7h
JMP Securities Downgrades Syros Pharmaceuticals (SYRS)
Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...
HCI Group, Inc. (NYSE:HCI) Shares Sold by Chartwell Investment Partners LLC
Chartwell Investment Partners LLC cut its position in shares of HCI Group, Inc. (NYSE:HCI – Free Report) by 47.0% in the 3rd ...
ETF Daily News16h
Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “market outperform” rating reissued by equities researchers at JMP Securities in a report issued on Tuesday,Benzinga reports. They ...
TipRanks on MSN1d
Syros downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...